Life Sciences Summit Brings Leaders in Academia and Industry to Map Out Next-Generation Medicines

Released: 15-Nov-2013 10:45 AM EST
Source Newsroom: Stony Brook University
Contact Information

Available for logged-in reporters only

Newswise — STONY BROOK, N.Y., November 15, 2013 – The Center for Biotechnology at Stony Brook University, in collaboration with Demy-Colton Life Science Advisors, and thought leaders from the biotech and biopharmaceutical industries, academia, medical research foundations, and investment community, has organized a two-day event to forge partnerships to accelerate the development of new treatments for some of the world’s most devastating diseases affecting millions. The Life Sciences Summit will be held at Convene-Midtown East in New York City November 20-21, 2013.

This conference promoting science and industry collaboration is a premier national translational science partnering event that brings emerging companies and innovators together with capital and industry with the goal of accelerating the development of new therapies. The event will feature 40 emerging companies and innovators and 70 industry experts and advisors, as well as representatives from the pharmaceutical industry, medical research foundations, and the early state venture capitalist community.

Presentation sessions include two tracts, one for emerging companies seeking investment and strategic partners, and the other for strategic partners seeking opportunities to in-license technology, forge collaborations or explore strategic alliances. New to the program is the Pipeline Café, a poster session that showcases academic innovations and pre-seed stage companies with the goal of increasing awareness and fostering relationships that will further asset development.

For more information about the conference, a complete list of sessions, and to register, see this link to the Life Sciences Summit.

About the Center for Biotechnology at Stony Brook University
The Center for Biotechnology is a cooperative research and development partnership between universities, private industry and New York State. It is involved in the discovery and early stage development of commercially promising technologies resulting from academic research, and the creation of strategic infrastructure that promotes the growth of the life sciences industry. The Center for Biotechnology has contributed to the development of more than a dozen approved products including ReoPro, Oracea, Cavistat, V3D Colon Virtual Colonoscopy and Exogen Bone Healing System. It has also helped launch eighteen companies.

About Demy-Colton Life Science Advisors
Demy-Colton Life Science Advisors was founded in 2008, by Sara Jane Demy, formerly VP for Business Development and Investor Relations at BIO. Since its establishment, Demy-Colton has launched the Biotech Showcase, contributed to the development of the Life Sciences Summit, and conceived and developed Partnering for Cures, now a Milken Institute/FasterCures program. Demy-Colton has also provided strategic advice to select life science industry organizations.

###


Comment/Share